Mucin 1 and poly I:C activates dendritic cells and effectively eradicates pituitary tumors as a prophylactic vaccine

Sui,Dehua; Ma,Lixin; Li,Meng; Shao,Wei; Du,Hongpeng; Li,Ke; Li,Zhenzhu; Li,Zefu

doi:10.3892/mmr.2016.4964

Mucin 1 and poly I:C activates dendritic cells and effectively eradicates pituitary tumors as a prophylactic vaccine

Authors:
- Dehua Sui
- Lixin Ma
- Meng Li
- Wei Shao
- Hongpeng Du
- Ke Li
- Zhenzhu Li
- Zefu Li
View Affiliations

Affiliations: Department of Neurosurgery, Affiliated Hospital of Binzhou Medical College, Binzhou, Shandong 256603, P.R. China
Published online on: March 2, 2016 https://doi.org/10.3892/mmr.2016.4964
Pages: 3675-3683

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pituitary tumors are the most common type of cancer within the central nervous system. In the present study, the expression levels of mucin 1 (Muc1) were examined in invasive and non‑invasive pituitary tumor samples, and the results of immunohistochemical staining and Western blot analysis demonstrated marked positive expression of Muc1. In addition, Muc1 + polyinosinic:polycytidylic acid (poly I:C) was found to stimulate the expression levels of the surface molecules cluster of differentiation (CD)40, CD83 and CD80, and HLA‑DRm and decreased the expression of CD14 in the dendritic cells, determined using fluorescence‑activated cell sorting. The secretions of interleukin (IL)‑6, tumor necrosis factor‑α and IL‑1β cytokines were also significantly induced, in a dose‑dependent manner. In in vivo experiments, a higher percentage of CD3+CD4+ T lymphocytes was detected, and the levels of interferon‑γ and IL‑2 in the splenocytes were also upregulated. Furthermore, the combination treatment of Muc1 with poly I:C increased anti‑Muc1 IgM and anti‑Muc1 IgG titers, and altered the balance of IgG2a and IgG1, all of which increased the T helper (Th)1 polarized immune response. Thus, the tumor antigen, Muc1, with poly I:C may produce potent protective effects, which polarize immune responses towards Th1, and elicit antitumor immunity to inhibit the progression of pituitary tumors.

View Figures

View References

1	Loyo-Varela M, Herrada-Pineda T, Revilla-Pacheco F and Manrique-Guzman S: Pituitary tumor surgery: Review of 3004 cases. World Neurosurg. 79:331–336. 2013. View Article : Google Scholar
2	Salehi F, Kovacs K, Scheithauer BW, Lloyd RV and Cusimano M: Pituitary tumor-transforming gene in endocrine and other neoplasms: A review and update. Endocr Relat Cancer. 15:721–743. 2008. View Article : Google Scholar : PubMed/NCBI
3	Boutros C, Cheng-Robles D and Goldenkranz R: Intestinal neuroendocrine tumor in a patient with pituitary adenoma. A case report and review of the current screening recommendations. J Med Case Rep. 1:1402007. View Article : Google Scholar : PubMed/NCBI
4	Sogani J, Yang W, Lavi E, Zimmerman RD and Gupta A: Sellar collision tumor involving metastatic lung cancer and pituitary adenoma: Radiologic-pathologic correlation and review of the literature. Clin Imaging. 38:318–321. 2014. View Article : Google Scholar : PubMed/NCBI
5	Ironside JW: Best practice No 172: Pituitary gland pathology. J Clin Pathol. 56:561–568. 2003. View Article : Google Scholar : PubMed/NCBI
6	Nistor RF: Parasellar classification of pituitary adenomas. Neurosurgery. 35:542–544. 1994.PubMed/NCBI
7	Kovacs K, Horvath E and Vidal S: Classification of pituitary adenomas. J Neurooncol. 54:121–127. 2001. View Article : Google Scholar
8	Sánchez-Tejada L, Sánchez-Ortiga R, Moreno-Pérez O, Montañana CF, Niveiro M, Tritos NA and Alfonso AM: Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness. Endocrinol Nutr. 60:358–367. 2013. View Article : Google Scholar : PubMed/NCBI
9	Matsuno A, Teramoto A, Takekoshi S, Sanno N, Osamura RY and Kirino T: Expression of plurihormonal mRNAs in somatotrophic adenomas detected using a nonisotopic in situ hybridization method: Comparison with lactotrophic adenomas. Hum Pathol. 26:272–279. 1995. View Article : Google Scholar : PubMed/NCBI
10	Baskar R, Lee KA, Yeo R and Yeoh KW: Cancer and radiation therapy: Current advances and future directions. Int J Med Sci. 9:193–199. 2012. View Article : Google Scholar : PubMed/NCBI
11	Bergmann-Leitner ES, Duncan EH and Leitner WW: Identification and targeting of tumor escape mechanisms: A new hope for cancer therapy? Curr Pharm Des. 9:2009–2023. 2003. View Article : Google Scholar : PubMed/NCBI
12	Ahmed S, Pahwa P, Fields A, Chandra-Kanthan S, Iqbal N, Zaidi A, Reeder B, Plaza FA, Zhu T and Leis A: Predictive factors of the use of systemic therapy in stage iv colorectal cancer: Who gets chemotherapy? Oncology. 88:289–297. 2015. View Article : Google Scholar : PubMed/NCBI
13	Voloshin T, Voest EE and Shaked Y: The host immunological response to cancer therapy: An emerging concept in tumor biology. Exp Cell Res. 319:1687–1695. 2013. View Article : Google Scholar : PubMed/NCBI
14	Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM and Small EJ: Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer. 107:67–74. 2006. View Article : Google Scholar : PubMed/NCBI
15	Thara E, Dorff TB, Pinski JK and Quinn DI: Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas. 69:296–303. 2011. View Article : Google Scholar : PubMed/NCBI
16	Mao Q, Li L, Zhang C, Sun Y, Liu S and Cui S: Clinical effects of immunotherapy of DC-CIK combined with chemotherapy in treating patients with metastatic breast cancer. Pak J Pharm Sci. 28(3 Suppl): 1055–1058. 2015.PubMed/NCBI
17	Shi YJ, Ren HY, Cen XN, Dong YJ, Ma MX, Zhao YL, Zhu Y and Yu JR: Dendritic cells elicit cellular immune response by targeting to capture breast cancer cells. Zhonghua zhong liu za zhi. 30:107–111. 2008.In Chinese. PubMed/NCBI
18	Chen W, Rains N, Young D and Stubbs RS: Dendritic cell-based cancer immunotherapy: Potential for treatment of colorectal cancer? J Gastroenterol Hepatol. 15:698–705. 2000. View Article : Google Scholar : PubMed/NCBI
19	Carmi Y, Spitzer MH, Linde IL, Burt BM, Prestwood TR, Perlman N, Davidson MG, Kenkel JA, Segal E, Pusapati GV, et al: Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature. 521:99–104. 2015. View Article : Google Scholar : PubMed/NCBI
20	Ahmed Ali HA, Di J, Mei W, Zhang YC, Li Y, Du ZW and Zhang GZ: Antitumor activity of lentivirus-mediated interleukin -12 gene modified dendritic cells in human lung cancer in vitro. Asian Pac J Cancer Prev. 15:611–616. 2014. View Article : Google Scholar : PubMed/NCBI
21	Bilusic M, Heery C and Madan RA: Immunotherapy in prostate cancer: Emerging strategies against a formidable foe. Vaccine. 29:6485–6497. 2011. View Article : Google Scholar : PubMed/NCBI
22	Pardoll D and Drake C: Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med. 209:201–0209. 2012. View Article : Google Scholar : PubMed/NCBI
23	Corfield AP: Mucins: A biologically relevant glycan barrier in mucosal protection. Biochim Biophys Acta. 1850:236–252. 2015. View Article : Google Scholar
24	Kao CJ, Wurz GT, Monjazeb AM, Vang DP, Cadman TB, Griffey SM, Wolf M and DeGregorio MW: Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model. Cancer Immunol Res. 2:581–589. 2014. View Article : Google Scholar : PubMed/NCBI
25	Pérez-Sánchez J, Estensoro I, Redondo MJ, Calduch-Giner JA, Kaushik S and Sitjà-Bobadilla A: Mucins as diagnostic and prognostic biomarkers in a fish-parasite model: Transcriptional and functional analysis. PLoS One. 8:e654572013. View Article : Google Scholar : PubMed/NCBI
26	Asano R, Takemura S, Tsumoto K, Sakurai N, Teramae A, Ebara S, Katayose Y, Shinoda M, Suzuki M, Imai K, et al: Functional construction of the anti-mucin core protein (MUC1) antibody MUSE11 variable regions in a bacterial expression system. J Biochem. 127:673–679. 2000. View Article : Google Scholar : PubMed/NCBI
27	Cao X, Zhang W, Wan T, He L, Chen T, Yuan Z, Ma S, Yu Y and Chen G: Molecular cloning and characterization of a novel CXC chemokine macrophage inflammatory protein-2 gamma chemoattractant for human neutrophils and dendritic cells. J Immunol. 165:2588–2595. 2000. View Article : Google Scholar : PubMed/NCBI
28	Costa CI, Delgado IF, de Costa JA, de Carvalho RF, Mouta Sda S Jr, Vianna CO and de Moraes MT: Establishment and validation of an ELISA for the quantitation of HBsAg in recombinant hepatitis B vaccines. J Virol Methods. 172:32–037. 2011. View Article : Google Scholar
29	Jones N, Agrawal D, Elrefaei M, Hanson A, Novitsky V, Wong JT and Cao H: Evaluation of antigen-specific responses using in vitro enriched T cells. J Immunol Methods. 274:139–147. 2003. View Article : Google Scholar : PubMed/NCBI
30	Holdsworth SR, Kitching AR and Tipping PG: Th1 and Th2 T helper cell subsets affect patterns of injury and outcomes in glomerulonephritis. Kidney Int. 55:1198–1216. 1999. View Article : Google Scholar : PubMed/NCBI
31	Muraille E and Leo O: Revisiting the Th1/Th2 paradigm. Scand J Immunol. 47:1–9. 1998. View Article : Google Scholar : PubMed/NCBI
32	Mishra J, Drummond J, Quazi SH, Karanki SS, Shaw JJ, Chen B and Kumar N: Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis. Crit Rev Oncol Hematol. 86:232–250. 2013. View Article : Google Scholar :
33	Kirkwood JM, Moschos S and Wang W: Strategies for the development of more effective adjuvant therapy of melanoma: Current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin Cancer Res. 12(Suppl): S2331–S2336. 2006. View Article : Google Scholar
34	Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC and Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The eastern cooperative oncology group trial EST 1684. J Clin Oncol. 14:7–17. 1996.PubMed/NCBI
35	Terando A, Sabel MS and Sondak VK: Melanoma: Adjuvant therapy and other treatment options. Curr Treat Options Oncol. 4:187–199. 2003. View Article : Google Scholar : PubMed/NCBI
36	Krishnan L, Deschatelets L, Stark FC, Gurnani K and Sprott GD: Archaeosome adjuvant overcomes tolerance to tumor-associated melanoma antigens inducing protective CD8 T cell responses. Clin Dev Immunol. 2010:5784322010. View Article : Google Scholar
37	Mechl Z and Kopecny J: Current results with surgery and adjuvant chemotherapy in malignant melanoma. Arch Geschwulstforsch. 56:367–371. 1986.In German.
38	Inao T, Harashima N, Monma H, Okano S, Itakura M, Tanaka T, Tajima Y and Harada M: Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly (I:C), on human breast cancer. Breast Cancer Res Treat. 134:89–100. 2012. View Article : Google Scholar
39	Huang YK, Zheng Z, Cheng CX, Wang LY, Li YR and Qiu F: The antitumor effect of the toll-like receptor 3 ligand polyinosinic-cytidylic acid as an adjuvant. Cancer Immunol Immunother. 62:237–244. 2013. View Article : Google Scholar
40	Martinez-Gil L, Goff PH, Hai R, Garcia-Sastre A, Shaw ML and Palese P: A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant. J Virol. 87:1290–1300. 2013. View Article : Google Scholar :
41	Ebner S, Ratzinger G, Krosbacher B, Schmuth M, Weiss A, Reider D, Kroczek RA, Herold M, Heufler C, Fritsch P and Romani N: Production of IL-12 by human monocyte-derived dendritic cells is optimal when the stimulus is given at the onset of maturation, and is further enhanced by IL-4. J Immunol. 166:633–641. 2001. View Article : Google Scholar
42	Lindstedt M, Johansson-Lindbom B and Borrebaeck CA: Global reprogramming of dendritic cells in response to a concerted action of inflammatory mediators. Int Immunol. 14:1203–1213. 2002. View Article : Google Scholar : PubMed/NCBI
43	Yang Y, Ochando J, Yopp A, Bromberg JS and Ding Y: IL-6 plays a unique role in initiating c-Maf expression during early stage of CD4 T cell activation. J Immunol. 174:2720–2729. 2005. View Article : Google Scholar : PubMed/NCBI